Philips reaches DOJ agreement over device recall, books €288 million provision in Q3

Koninklijke Philips has reached an agreement in principle with the United States Department of Justice concerning a recall of its sleep apnea devices. As part of this development, the company has booked a provision of €288 million in its third-quarter financial results to address the settlement. This action is tied specifically to the recall of its sleep machines, which are used to treat sleep apnea. The company announced these updates alongside its 2026 third-quarter results, indicating a strategic move to resolve long-standing legal issues with U.S. regulators regarding the Respironics devices. Various financial and industry outlets have emphasized the scale of the provision and the timing of the announcement.

Reuters and MassDevice both report that the company set aside €288 million for the settlement, while Fierce Biotech notes a proposed DOJ settlement amount of $322 million. Dutch-focused publications, including NL Times and DutchNews.nl, highlight the resolution of the sleep apnea case with U.S. regulators. Additionally, Morningstar describes the situation as Philips almost closing the chapter on the Respironics recall, while noting that the general business results remain decent. This development is critical because the recall of sleep apnea devices has been a primary point of contention for the company. According to the Wall Street Journal, Philips shares have risen following reports of stronger profitability, which has helped revive confidence among investors.

The context of this settlement is framed by the company's Q3 earnings call, as detailed by TradingView and Yahoo Finance. The provision represents a formal financial acknowledgment of the liabilities associated with the recall process and the subsequent regulatory scrutiny from the U.S. government. Future attention will likely focus on the finalization of the agreement in principle and the impact of the €288 million provision on the company's overall financial trajectory. Investors and regulators will be monitoring whether this settlement fully resolves the legal challenges associated with the CPAP and sleep apnea machine recalls. Coverage from 10TV and official company statements regarding third-quarter results indicate that profitability is a key metric for the company as it moves forward from these regulatory hurdles.